Endologix, Inc. and TriVascular Technologies, Inc. Complete Merger
Feb 03, 2016 21:01 pm UTC| Business
IRVINE, Calif., Feb. 03, 2016 -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has successfully completed the previously announced merger...
Amicus Therapeutics to Present at the Leerink Partners 5th Annual Global Healthcare Conference
Feb 03, 2016 21:01 pm UTC| Business
CRANBURY, N.J., Feb. 03, 2016 -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will...
Feb 03, 2016 21:01 pm UTC| Business
CAMBRIDGE, Mass., Feb. 03, 2016 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the company is scheduled to present at the...
Kessler Foundation Receives $1 M Grant to Study Benefits of Ekso Bionics' Ekso GT™ Exoskeleton
Feb 03, 2016 21:01 pm UTC| Business
RICHMOND, Calif., Feb. 03, 2016 -- Kessler Foundation, a global leader in rehabilitation research, announced today that it will use the Ekso GT™ of Ekso Bionics (OTCQB:EKSO) in a multi-center randomized controlled trial...
Fate Therapeutics to Present at Leerink Partners 5th Annual Global Healthcare Conference
Feb 03, 2016 21:01 pm UTC| Business
SAN DIEGO, Feb. 03, 2016 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders, announced today that...
Skyline Medical to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
Feb 03, 2016 21:00 pm UTC| Business
MINNEAPOLIS, Feb. 03, 2016 -- Skyline Medical Inc. (NASDAQ:SKLN)(NASDAQ:SKLNU) today announced that Josh Kornberg, President and CEO, will provide a company overview at the Source Capital Group’s 2016 Disruptive Growth ...
Immunomedics Announces Second Quarter Fiscal 2016 Results and Clinical Program Developments
Feb 03, 2016 21:00 pm UTC| Business
MORRIS PLAINS, N.J., Feb. 03, 2016 -- Immunomedics, Inc., (Nasdaq:IMMU) today reported financial results for the second quarter ended December 31, 2015. The Company also highlighted recent key developments and planned...
The “Takaichi Trade”: How Japan’s First Female PM Is Shaping the Yen
How the US–India tariff truce boosts major Indian industries, Surat to Pharma